Litigation News

Texas Attorney General Ken Paxton sued Bristol-Myers Squibb and Sanofi in November 2025, alleging failure to disclose that blood thinner Plavix has reduced efficacy in certain ethnic groups due to genetic factors. The lawsuit claims violations of state consumer protection laws, with millions of Texans improperly prescribed the medication, raising patient safety concerns and financial impact on taxpayer-funded healthcare programs.

Amgen filed a BPCIA complaint in New Jersey federal court against Alkem Laboratories, Ascend Laboratories, and Enzene Biosciences over Alkem's biosimilar application for PROLIA and XGEVA (denosumab). Amgen alleges Alkem failed to properly disclose BLA information during patent dance negotiations and imported infringing materials. The complaint asserts 35 patents and seeks injunctive relief and damages. This marks Amgen's eleventh denosumab biosimilar litigation, with five previous cases settled and others pending.

SCOTUS declined to hear Gesture Technology Partners LLC's appeal challenging PTAB's authority to review expired patents. Gesture sued Apple, Google, and LG for camera-sensing patent infringement before the patent expired in 2020. The defendants successfully petitioned PTAB to invalidate the patent. The Federal Circuit upheld the invalidation. By refusing certiorari, SCOTUS preserved PTAB's ability to conduct patent review even after patent expiration, strengthening administrative challenges over expired patents.

Oura sued Samsung in US District Court over patent No. 11,868,178 for "Wearable Computing Device," alleging Galaxy Ring infringes technology for rings with integrated sensors, electronics, and curved batteries. The lawsuit also targets Noise, Reebok, and Zepp Health, seeking royalty payments. Samsung previously filed a dismissed countersuit arguing Oura's patents were overly broad. Oura has secured licensing fees from Circular and Ringconn, while Ultrahuman contests a US sales ban. The outcome could significantly impact the expanding smart-ring market's intellectual property landscape.

Bausch Health defeated investor fraud allegations in federal court. Judge Zahid N. Quraishi dismissed the proposed class action with finality, ruling investors failed to sufficiently allege false or misleading statements after multiple pleading attempts. The case centered on claims Bausch Health concealed the true reasons for spinning off Bausch & Lomb and misrepresented drug patent strength. The court found the fraud allegations inadequately supported.

Komax Group filed patent infringement lawsuit against Chinese competitor Hacint Intelligence Technology Co., Ltd. Komax, which holds over 1,200 patents, utility models, and design rights globally in automated wire processing technology, alleges probable infringement of several patents. The company's intellectual property portfolio protects machines, processes, and products derived from patented processes. Komax maintains strategy of enforcing IP rights against violations as market and technology leader in automated wire processing.

Whirlpool filed an ITC complaint against Samsung Electronics and LG Electronics, alleging patent infringement on over-the-range microwave ovens and requesting import/sales bans. Samsung faced 97 U.S. patent lawsuits in 2023, including a $191.4 million jury verdict to Pictiva Displays for OLED patent infringement. LG won a decade-long patent dispute with Mondis Technology and Maxell, overturning $14.3 million damages. Non-practicing entities filed 80.4% of cases against Korean companies, targeting large settlements.

Federal Circuit denied Motorola Solutions' mandamus petition challenging IPR deinstitution, ruling petitioners lack appeal rights under 35 U.S.C. § 314(d). Court reversed indefiniteness invalidity ruling for Canatex Completion Solutions' oil/gas well patent, applying judicial correction to fix evident clerical error. In Smartrend Manufacturing v. Opti-Luxx, Court reversed utility patent infringement judgment, finding accused illuminated school bus sign lacks required removable sign capability, and remanded design patent infringement for new trial after correcting claim construction.

The CJEU's BSH ruling enables EU courts to hear cross-border patent cases when defendants are domiciled in the forum state, including for non-EU patents. The UPC's Mannheim and Hamburg divisions issued injunctions covering non-UPC states in Fujifilm v Kodak and Dyson v Dreame. Munich Regional Court granted Regeneron and Bayer injunctions across 22 European countries. US entity Onesta IP sued BMW in German courts over US patent infringement, testing BSH's jurisdictional boundaries in international patent disputes.

Corcept Therapeutics faces ongoing patent litigation with Teva and antitrust concerns that pose key investment risks. Wolfe Research initiated coverage with Peerperform rating, citing these legal challenges alongside the company's pending FDA decision on relacorilant for hypercortisolism (PDUFA date December 30, 2025). The patent disputes could overshadow revenue prospects if outcomes turn negative, creating uncertainty around the company's ability to diversify beyond its Korlym drug and achieve projected growth targets.